- Home
- CYD vs MREO Comparison
CYD vs MREO Comparison
Compare CYD & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYD | MREO |
|---|---|---|
| Founded | 1951 | 2015 |
| Country | Singapore | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 324.6M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | CYD | MREO |
|---|---|---|
| Price | $35.75 | $2.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 121.9K | ★ 2.6M |
| Earning Date | 08-08-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ 40.10 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $3,159,401,156.00 | $500,000.00 |
| Revenue This Year | $41.12 | N/A |
| Revenue Next Year | $6.93 | $163.84 |
| P/E Ratio | $21.53 | ★ N/A |
| Revenue Growth | ★ 17.99 | N/A |
| 52 Week Low | $8.80 | $1.47 |
| 52 Week High | $42.60 | $3.88 |
Technical Indicators
Market Signals| Indicator | CYD | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 63.51 |
| Support Level | $34.54 | $1.89 |
| Resistance Level | $37.65 | $2.36 |
| Average True Range (ATR) | 1.03 | 0.15 |
| MACD | 0.15 | 0.02 |
| Stochastic Oscillator | 41.16 | 85.57 |
Price Performance
Historical ComparisonAbout CYD China Yuchai International Limited
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).